Efficacy of Danlou Tablet in Patients with Non-ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo-Controlled, Randomized Trial
Table 3
MACE at 30 days after PCI in the Danlou Tablet and placebo groups.
Incidence
Treatment difference (%)
Danlou Tablet group
Placebo group
Differenc of incidence (95% CI)
value
Full-analysis set
Total MACE, (%)
24 (22.0)
37 (33.6)
1.8 (1.0, 3.3)
0.0
Cardiac death, (%)
0
0
Nonfatal MI, (%)
24 (22.0)
37 (33.6)
1.8 (1.0, 3.3)
0.0
Target vessel revascularization, (%)
0
1 (0.9)
1.
Rehospitalization due to CV, (%)
0
0
Per-protocol analysis set
Total MACE, (%)
24 (22.4)
36 (33.0)
1.7 (0.9, 3.1)
0.0
Cardiac death, (%)
0 (0)
0 (0)
Nonfatal myocardial infarction, (%)
24 (22.4)
36 (33.0)
1.7 (0.9, 3.1)
0.0
Target vessel revascularization, (%)
0
1 (0.9)
1.
Rehospitalization due to CV, (%)
0
0
CI, confidence interval; CVE, cardiovascular events; MACE, major adverse cardiac event; and MI, myocardial infarction. ifference of incidence = Danlou Tablet − placebo. ardiovascular events included severe angina or heart failure (NYHF ⩾ IV). value is from the continuity-adjusted Chi-square test. value is from Fisher’s exact test.
